Alkermes (ALKS) Other Non-Current Liabilities (2011 - 2026)
Alkermes (ALKS) posted quarterly Other Non-Current Liabilities of $136.3 million for Q2 2026, up 143.2% year-over-year from $56.0 million in Q2 2025, and up 24.49% quarter-over-quarter from $109.5 million in Q1 2026.
Alkermes (ALKS) Other Non-Current Liabilities (2011 - 2026) Analysis & Trends
Alkermes (ALKS) has reported Other Non-Current Liabilities for 16 consecutive years, with $136.3 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Other Non-Current Liabilities rose 143.2% year-over-year to $136.3 million; the TTM figure through Jun 2026 stood at $136.3 million (up 143.2% YoY), while the FY2025 annual figure was $61.0 million, up 8.91% from the prior year.
- Other Non-Current Liabilities improved to $136.3 million in Q2 2026 per ALKS's latest filing, from $109.5 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $136.3 million in Q2 2026 and bottomed at $42.4 million in Q4 2022.
- Historically, Other Non-Current Liabilities has averaged $58.8 million across 5 years, with a median of $51.3 million in 2023.
- Annual changes were most pronounced in 2022 — Other Non-Current Liabilities decreased 2.9% — and 2026, when it surged 143.2%.
- Alkermes' Other Non-Current Liabilities stood at $42.4 million in 2022, then rose by 17.68% to $49.9 million in 2023, then rose by 12.31% to $56.0 million in 2024, then rose by 8.91% to $61.0 million in 2025, then soared by 123.42% to $136.3 million in 2026.
- Business Quant data shows ALKS's Other Non-Current Liabilities at $136.3 million in Q2 2026, $109.5 million in Q1 2026, and $61.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn |
| 3 | Zoetis | 31.79 Bn | 30.11 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.69 Bn | 22.89 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.58 Bn | 683.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - |
| 10 | Alkermes | 8.15 Bn | 7.49 Bn | 397.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 136.30 Mn |
| Mar 31, 2026 | 109.49 Mn |
| Dec 31, 2025 | 61.01 Mn |
| Sep 30, 2025 | 56.75 Mn |
| Jun 30, 2025 | 56.05 Mn |
| Mar 31, 2025 | 58.85 Mn |
| Dec 31, 2024 | 56.02 Mn |
| Sep 30, 2024 | 52.63 Mn |
| Jun 30, 2024 | 48.29 Mn |
| Mar 31, 2024 | 48.96 Mn |
| Dec 31, 2023 | 49.88 Mn |
| Sep 30, 2023 | 53.62 Mn |
| Jun 30, 2023 | 48.22 Mn |
| Mar 31, 2023 | 48.49 Mn |
| Dec 31, 2022 | 42.38 Mn |
| Sep 30, 2022 | 42.86 Mn |
| Jun 30, 2022 | 45.21 Mn |
| Mar 31, 2022 | 43.91 Mn |
| Dec 31, 2021 | 43.65 Mn |
| Sep 30, 2021 | 32.12 Mn |